Longeveron Closes $5 Million Public Stock Offering

Longeveron ( (LGVN) ) has issued an announcement.

On August 8, 2025, Longeveron announced the pricing of a public offering of its Class A common stock, which closed on August 11, 2025. The offering, managed by H.C. Wainwright & Co., is expected to generate approximately $5 million upfront, with an additional potential $12.5 million from short-term warrants. The proceeds will support the development of laromestrocel for various conditions and regulatory activities.

The most recent analyst rating on (LGVN) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Longeveron stock, see the LGVN Stock Forecast page.

Spark’s Take on LGVN Stock

According to Spark, TipRanks’ AI Analyst, LGVN is a Neutral.

Longeveron’s overall stock score is primarily impacted by its financial performance and technical analysis, both of which highlight significant challenges. The company’s operational losses and bearish technical indicators weigh heavily on the score. However, the recent FDA approval for a pivotal clinical trial provides a positive outlook, offering potential future growth opportunities.

To see Spark’s full report on LGVN stock, click here.

More about Longeveron

Longeveron is a clinical stage biotechnology company focused on developing regenerative medicines for life-threatening, rare pediatric, and chronic aging-related conditions. Their lead product, laromestrocel (Lomecel-B™), is an allogeneic mesenchymal stem cell therapy with potential applications across various diseases, including hypoplastic left heart syndrome, Alzheimer’s disease, and pediatric dilated cardiomyopathy.

Average Trading Volume: 504,077

Technical Sentiment Signal: Sell

Current Market Cap: $10.29M

See more data about LGVN stock on TipRanks’ Stock Analysis page.